NCT03650595Recruiting
MRI Guided Focal Laser Ablation of Prostate Cancer
Source: ClinicalTrials.gov · Last updated 5 Jun 2026
Brief summary (registry, in English)
This clinical research study is designed to determine the ability of in bore MRI guided Focal Laser Ablation (MRgFLA) in patients with early stage carcinoma of prostate. The results will be evaluated by repeated MRI and prostate biopsy. Previous prospective development study demonstrated that FLA may be a viable option for men with low-intermediate risk prostate cancer. The vast majority of patients undergoing this treatment experienced minimal side effects with no peri-operative complications. Over 80% of patients treated with MRgFLA remain on AS and were able to avoid radical therapy at mean follow up duration of 3 years.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 102 (estimated)
- First submitted
- 10 Aug 2018
- Start date
- 29 Mar 2018
- Primary completion date
- 30 Dec 2027
- Lead sponsor
- University Health Network, Toronto
- Diseases
- Prostate cancer
- NCT number
- NCT03650595
What you commit to
- Study type: Interventional
- Planned participants: 102
- From 29 Mar 2018 to the primary completion date, 30 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Medically unfit for focal therapy of the prostate
- Patients who have received androgen suppression therapy
- Patients who have received or are receiving chemotherapy for prostate carcinoma;
- Patients previously treated with surgery to the prostate (traditional, endoscopic or minimally invasive including HIFU, TUNA, RITA, microwave, cryotherapy or any curative treatment
- Patients who have participated in a clinical study and/or received treatment with an investigational treatment and/or product within the past 90 days;
Other illness
- Patients who have undergone radiation therapy for prostate cancer or to the pelvis
- Any condition, or history of illness or surgery that, in the opinion of the Investigator, might confound the results of the study or pose additional risks to the patient (e.g. significant cardiovascular conditions or allergies);
- Patients with a history of noncompliance with medical therapy and/or medical recommendations;
- Chronic or acute prostatitis, neurogenic bladder, urinary tract infection, sphincter abnormalities, or any other symptom that prevents normal micturition.
- Patients with contraindication to MRI (i.e. pacemaker, hip prosthesis, severe claustrophobia, brain aneurysm clip, allergy to MRI contrast agent)
- Any condition, or history of illness that, in the opinion of the investigator will confound or increase the patient risk during the study
Other
- Patients who are unwilling or unable to give informed consent;
- Patients who are unwilling or unable to complete the patient self-assessment questionnaires;
Who the study is looking for
- Men 40-80 years of age
- Histologically proven low-intermediate risk prostate carcinoma; (Gleason score ≤ 7, primary grade ≤ 4;)
- Prostate cancer clinical stage T1c and T2
- MR site suspicious for cancer or cancer mapped to one lobe of the prostate using the 3D hybrid TRUS device
- Size of MR visible tumor \<20mm
- Suspicious site on Prostate MRI must coincide with sector positive for cancer on biopsy
- Prostate specific antigen (PSA) level \<15 ng/mL
- IPSS, ICIQ-UI-SF, IIEF complete prior to procedure
- Life expectancy of greater than 10 years, based on co-morbidity not related to prostate cancer.
Age in the registry: 40 years to 80 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sangeet Ghai, MD Coordinator of this site? Confirm its status | Toronto | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.